Assessment of Local Retention and Duration of Activity of SPL7013 Following Vaginal Application of 3% SPL7013 Gel (VivaGel) in Healthy Volunteers.
Phase of Trial: Phase I/II
Latest Information Update: 13 Aug 2012
At a glance
- Drugs Astodrimer (Primary)
- Indications Herpes simplex virus type 2 infections; HIV infections
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Starpharma
- 04 Aug 2009 Results reported in a Starpharma Holdings media release.
- 10 Jun 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 10 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.